Psycheceutial Biosciences (BWVI) Listed on WeFunder!
Psycheceutical’s Psychedelic Experience, a Safer More Viable Choice in Getting Treated.
Imagine the benefits of psychedelics, without hallucinating!
Zappy Zapolin Hopes To Put Ibogaine Front And Center For Addiction
“The only legitimate addiction interrupter capable of breaking a heroin, meth, opiate, or alcohol addiction in a single 12-hour session.”
Psycheceutical’s (BWVI) Delivery Tech is Grabbing Attention. Will Pharma Listen?
A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen? PharmaVoice
Psycheceutical is developing a back-of-the-neck topical treatment...
COMPASS Pathways (CMPS) Announces Up to $285 Million Private Placement
Transaction led by healthcare specialist investors, TCGX and Aisling Capital
$125 million financing upfront with up to...
Billionaire, Point 72’s Steve Cohen, Continues to Support Psychedelic Research.
Cohen Psychedelic Research & Health Initiative
Cohen Foundation Awards $5 Million for MDMA Therapy Approval
Millions...
Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within Minutes, With no...
Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests...
Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials
Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD.
Company raises $1.3M USD convertible note...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
Video: New Topical Drug Delivery System, NeuroDirect™
Must Watch Video. Topical Application to Improve Delivery of FDA-Approved Drugs.
https://youtu.be/2CGT7P9QEvo
Can...
Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...